公开(公告)号：US4840941A

公开(公告)日：1989-06-20

申请号：US144131

申请日：1988-01-15

申请人： Ryuzo Ueno ,  Ryuji Ueno ,  Sachiko Kuno ,  Akihiko Tabata

发明人： Ryuzo Ueno ,  Ryuji Ueno ,  Sachiko Kuno ,  Akihiko Tabata

IPC分类号： A61K31/715 ,  C07H11/00

CPC分类号： C07H11/00 ,  A61K31/715

摘要： Method of treatment of diseases caused by retroviruses which comprises administering therapeutically effective amount of a natural or synthetic oligo- or polysaccharide having at least one S-oxoacid group attached to the saccharic carbon atom through a linking group of lower molecular weight or a pharmaceutically acceptable salt thereof to a subject in need of such treatment.

摘要翻译： 治疗由逆转录病毒引起的疾病的方法，该方法包括给予治疗有效量的具有至少一个S-糖酸基团的天然或合成的寡糖或多糖，其通过低分子量的连接基团或药学上可接受的盐连接到糖质碳原子上 对于需要这种治疗的对象。

公开(公告)号：US08673973B2

公开(公告)日：2014-03-18

申请号：US11438290

申请日：2006-05-23

申请人： Ryuji Ueno

发明人： Ryuji Ueno

IPC分类号： A61K31/215

CPC分类号： A61K31/5575 ,  A61K9/0048 ,  A61K31/5377 ,  A61K31/557 ,  A61K47/186 ,  A61K47/26 ,  Y10S514/903

摘要： Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.

摘要翻译： 本发明提供一种治疗眼睛高血压和青光眼的方法，其具有减少的副作用，例如角膜结膜疾病和黄斑水肿，其包括给予需要所述治疗的受试者包含拉坦前列素作为其活性成分的眼用组合物，其中眼用组合物基本上包含 没有苯扎氯铵。

公开(公告)号：US08662221B2

公开(公告)日：2014-03-04

申请号：US12977253

申请日：2010-12-23

申请人： Ryuji Ueno ,  Misako Nakata

发明人： Ryuji Ueno ,  Misako Nakata

IPC分类号： B60K1/00

CPC分类号： B60L9/00 ,  B60L11/1816 ,  B60L11/182 ,  H02J5/005 ,  H02J7/025 ,  H02J50/10 ,  Y02T10/7005 ,  Y02T10/7072 ,  Y02T90/122 ,  Y02T90/14

摘要： In an electric vehicle, a power unit is installed in an internal space region of a tire of each of front and rear wheels. The unit has a plurality of power elements arranged on an inner peripheral surface of a ground contact portion of the tire. Each of the elements includes a core made of a permalloy, and a power coil wound around the core. When a periodically-changing magnetic field is generated in a region above a road by an electric supply arrangement installed in the road, each of the elements generates electric power. This electric power is supplied to a motor of the vehicle through a power distribution system. The motor drives front wheels. The electric vehicle can continuously run over long distances without charging a battery at a buttery station.

摘要翻译： 在电动车辆中，动力单元安装在前轮和后轮中的每一个的轮胎的内部空间区域中。 该单元具有布置在轮胎的接地部分的内周表面上的多个功率元件。 每个元件包括由坡莫合金制成的芯和缠绕在芯上的电力线圈。 当通过安装在道路中的供电装置在道路上方的区域中产生周期性变化的磁场时，每个元件产生电力。 该电力通过配电系统供给到车辆的电动机。 电机驱动前轮。 电动车可以连续运行很长距离，而无需在电池站充电。

公开(公告)号：US08592483B2

公开(公告)日：2013-11-26

申请号：US13566353

申请日：2012-08-03

申请人： Ryuji Ueno

发明人： Ryuji Ueno

IPC分类号： A01N37/08 ,  A61K31/557 ,  C07C59/185

CPC分类号： C07C405/00 ,  A61K31/5575

摘要： The present invention provides a novel fatty acid derivative. The present invention also provides a method for treating schizophrenia in a mammalian subject, which comprises administering to the subject in need thereof an effective amount of a fatty acid derivative.

摘要翻译： 本发明提供新的脂肪酸衍生物。 本发明还提供了哺乳动物受试者中治疗精神分裂症的方法，其包括向有需要的受试者施用有效量的脂肪酸衍生物。

公开(公告)号：US08389542B2

公开(公告)日：2013-03-05

申请号：US13330942

申请日：2011-12-20

申请人： Ryuji Ueno ,  Myra L. Patchen

发明人： Ryuji Ueno ,  Myra L. Patchen

IPC分类号： A61K31/44 ,  A61K31/34 ,  A61K31/19

CPC分类号： C07D311/94 ,  A61K31/557 ,  C07C53/23

摘要： A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in an amount of 24 μg+/−10%:

摘要翻译： 描述了用于治疗人类患者便秘的剂量单位。 本发明的剂量单位包括卤代前列腺素类似物和药学上合适的赋形剂。 剂量单位可减轻便秘，无明显副作用。 特别地，剂量单位包括由式（I）和/或其互变异构体表示的前列腺素（PG）类似物和药学上合适的赋形剂，其中所述剂量单位含有24μg+/- 10％的PG类似物：

公开(公告)号：US08236969B2

公开(公告)日：2012-08-07

申请号：US12762890

申请日：2010-04-19

申请人： Ryu Hirata ,  Tatsuya Matsukawa ,  Kazuhiro Masuzaki ,  Ryuji Ueno

发明人： Ryu Hirata ,  Tatsuya Matsukawa ,  Kazuhiro Masuzaki ,  Ryuji Ueno

IPC分类号： C07D309/12 ,  C07F7/18

CPC分类号： C07D307/93 ,  C07C405/0025 ,  C07D307/935 ,  C07D309/12 ,  C07D311/94

摘要： Disclosed is a method for preparing a prostaglandin derivative of formula (A): which comprises reacting an aldehyde represented by formula (1): with a 2-oxoalkyl phosphonate in a reaction solvent under the presence of alkali hydroxide as sole base. By carrying out the reaction using an alkali hydroxide as sole base in the reaction system, the desired prostaglandin derivative can be obtained by simple procedures and with high yield.

公开(公告)号：US20110034424A1

公开(公告)日：2011-02-10

申请号：US12826108

申请日：2010-06-29

申请人： Ryuji Ueno

发明人： Ryuji Ueno

IPC分类号： A61K31/60 ,  A61K31/405 ,  A61K31/353 ,  A61K31/407 ,  A61K31/5415 ,  A61K31/4152 ,  A61K31/416 ,  A61K31/515 ,  A61K31/47 ,  A61K31/44 ,  A61K31/381 ,  A61P29/00

CPC分类号： A61K31/192 ,  A61K31/352 ,  A61K31/5575 ,  A61K45/06 ,  A61K2300/00

摘要： Provided is a method for the long term treatment of a condition or disease which is one of the indications for NSAID use in a human patient, which comprises administering to the patient a pharmaceutically effective amount of a NSAID and at least 36 mcg per day of cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide. By administering cobiprostone or its pharmaceutically acceptable salt, ester, ether or amide in combination with a NSAID, the patient can receive the NSAID for longer time period.

摘要翻译： 本发明提供了一种长期治疗病人或疾病的方法，该病症或疾病是人类患者中NSAID使用的适应症之一，其包括向患者施用药学有效量的NSAID和每天至少36mcg的cob石 或其药学上可接受的盐，酯，醚或酰胺。 通过使用cobiprostone或其药学上可接受的盐，酯，醚或酰胺与NSAID组合，患者可以接受NSAID更长时间。

公开(公告)号：US07732487B2

公开(公告)日：2010-06-08

申请号：US10298062

申请日：2002-11-18

申请人： Ryuji Ueno

发明人： Ryuji Ueno

IPC分类号： A61K31/215 ,  A61K31/19

CPC分类号： A61K31/44 ,  A61K31/554 ,  A61K31/5575

摘要： Disclosed is a method for prophylactic or therapeutic treatment of a condition or disease responsive to opening of ClC-2 channel, which comprises the step of administrating an effective amount of a ClC-2 channel opener to a subject in need of said treatment. According to the invention, a tissue or organ to be transplanted can also be treated with the ClC-2 channel opener.

摘要翻译： 公开了一种对ClC-2通道开放起反应的病状或疾病的预防或治疗方法，其包括向需要所述治疗的受试者施用有效量的ClC-2通道开放剂的步骤。 根据本发明，也可以用ClC-2通道开放剂处理待移植的组织或器官。

公开(公告)号：US07253295B2

公开(公告)日：2007-08-07

申请号：US11333511

申请日：2006-01-18

申请人： Ryuji Ueno ,  John Cuppoletti

发明人： Ryuji Ueno ,  John Cuppoletti

IPC分类号： C07C23/00

CPC分类号： C07C405/00 ,  A61K31/557

摘要： Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transportation.

摘要翻译： 公开了前列腺素化合物作为氯化物通道开放剂的新用途。 根据本发明，哺乳动物受试者中的氯化物通道可以被前列腺素化合物打开以促进氯离子转运。

公开(公告)号：US20060205725A1

公开(公告)日：2006-09-14

申请号：US11438290

申请日：2006-05-23

申请人： Ryuji Ueno

发明人： Ryuji Ueno

IPC分类号： A61K31/5377

CPC分类号： A61K31/5575 ,  A61K9/0048 ,  A61K31/5377 ,  A61K31/557 ,  A61K47/186 ,  A61K47/26 ,  Y10S514/903

摘要： Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.